Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04710641
Title Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone (OUTREACH2)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mina Alpha Limited

hepatocellular carcinoma


CEBPA-51 + Sorafenib


Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope Recruiting Duarte California 91012 United States Details
National University Hospital Singapore Recruiting Singapore 119228 Singapore Details
*Shaded cells indicate that there was no data available from for the field